rc48-adc
In Expansion: Melanoma, Non-small Cell Lung Cancer
Novartis Pharmaceuticalsantibody_drug_conjugatePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the In Expansion: Melanoma, Non-small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
niz985 Novartis Pharmaceuticals | Phase 1 | CC |
Tislelizumab Novartis Pharmaceuticals | Phase 1 | CC |
Pyrotinib Novartis Pharmaceuticals | Phase 1 | CC |
Spartalizumab Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →